Edition:
United States

Orexo AB (ORX.ST)

ORX.ST on Stockholm Stock Exchange

52.00SEK
11:29am EDT
Change (% chg)

1.50kr (+2.97%)
Prev Close
50.50kr
Open
50.50kr
Day's High
52.00kr
Day's Low
49.50kr
Volume
44,011
Avg. Vol
65,691
52-wk High
77.75kr
52-wk Low
40.60kr

ORX.ST

Chart for ORX.ST

About

Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects... (more)

Overall

Beta: 1.41
Market Cap(Mil.): kr1,739.66
Shares Outstanding(Mil.): 34.45
Dividend: --
Yield (%): --

Financials

  ORX.ST Industry Sector
P/E (TTM): -- 39.19 39.69
EPS (TTM): -3.69 -- --
ROI: -15.85 15.23 14.44
ROE: -41.80 16.16 15.49

BRIEF-Orexo Q2 net earnings in line with expectations

* Says effective July 1st Zubsolv is only preferred buprenorphine/naloxone product within largest fee for service (ffs) medicaid program in U.S., state of Maryland

Jul 12 2016

BRIEF-Orexo signs license agreement with Mundipharma, which obtains ex-US global rights to Zubsolv

* signs license agreement with Mundipharma, which obtains ex-us global rights to Zubsolv

Jun 30 2016

BRIEF-AstraZeneca acquires rights to Orexo's OX-CLI project

* says AstraZeneca acquires all rights to Orexo's OX-CLI project

Mar 17 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters StreetEvents
$75.00
Provider : GlobalData
$300.00
Provider : Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.